Repare Therapeutics Inc.: M&A transaction — Repare sells Polθ inhibitor RP-3467 to Gilead for up to $30M; Xeno deal per-share value rises to ~$2.20

Repare Therapeutics Inc.

Gilead will pay up to $30M ($25M upfront + $5M transfer completion) for Repare's RP-3467 Polθ ATPase inhibitor program.
Repare retains other pipeline programs including RP-1664 and lunresertib/camonsertib.
Estimated per-share cash payment in pending Xeno acquisition increased to ~$2.20, up from prior estimate due to Gilead upfront cash.
Asset purchase closed Dec 23, 2025; consent obtained from NYU for assignment of related license agreement.
CEO Steve Forte noted this is Repare's third and most significant portfolio transaction in 2025.

item 1.01 item 2.01 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Repare Therapeutics Inc. completed a disposition involving Gilead Sciences, Inc. for up to $30,000,000 in cash (closed 2025-12-23).

Action: disposition
Counterparty: Gilead Sciences, Inc.
Consideration: up to $30,000,000 in cash
Closing: 2025-12-23

Exact text from the filing

contracts, cash, accounts receivable, real property or equipment. Pursuant to the Asset Purchase Agreement, Gilead will pay the Company an aggregate purchase price of up to $30,000,000 in cash, consisting of (i) a $22,000,000 payment due to the Company no later than December 31, 2025, (ii) a holdback amount of up to $3,000,000 that may become payable after one

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001193125-25-332236

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.